457889-46-2

Usage

Uses

Used in Organic Synthesis:
(4'-TRIFLUOROMETHYLBIPHENYL-4-YL)-METHANOL is used as a building block in organic synthesis for the preparation of other chemical compounds. Its unique structure allows it to be a valuable intermediate in the synthesis of various organic molecules.
Used in Pharmaceutical Industry:
(4'-TRIFLUOROMETHYLBIPHENYL-4-YL)-METHANOL may have potential applications in the pharmaceutical industry due to its structural features. Its trifluoromethyl and methanol groups could contribute to the development of new drugs with specific therapeutic properties. However, further research and testing are needed to fully understand its potential in this field.
Used in Agrochemical Industry:
Similarly, (4'-TRIFLUOROMETHYLBIPHENYL-4-YL)-METHANOL may also find use in the agrochemical industry, where its structural features could be leveraged to develop new agrochemicals with targeted effects on pests or diseases. Further investigation is required to explore its potential applications and benefits in this area.

Upstream product

• 647842-34-0 ethyl 4'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxylate 
• 873-75-6 4-bromobenzenemethanol 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 1122-91-4 4-bromo-benzaldehyde 
• 195457-71-7 4-[4-(trifluoromethyl)phenyl]benzoic acid 
• 127783-73-7 methyl 4’-(trifluoromethyl)-[1,1’-biphenyl]-4-carboxylate 
• 90035-34-0 4-(4-trifluoromethylphenyl)benzaldehyde 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 59016-93-2 p-hydroxymethylphenylboronic acid 

Downstream Products

• 934753-43-2 methyl 4-[(4E)-3-(4-cyanobenzyl)-5-(2-{[4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)pent-4-en-1-yl]benzoate 
• 935253-34-2 Methyl 4-[(4E)-3-[4-(1H-tetrazol-5-yl)benzyl]-5-(2-{[4'-(trifluoromethyl)biphenyl-4-yl]methoxy}-phenyl)pent-4-en-1-yl]benzoate 
• 935253-61-5 4-[(4E)-3-[4-(1H-Tetrazol-5-yl)benzyl]-5-(2-{[4'-(trifluoromethyl)biphenyl-4-yl]-methoxy}phenyl)pent-4-en-1-yl}benzoic acid 
• 1030367-87-3 2-methyl-4-((2-phenyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)thio)phenol 
• 1030367-80-6 tert-butyl dimethyl(2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenoxy)silane 
• 1030367-81-7 tert-butyl dimethyl(2-methyl-4-((2-phenyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)thio)phenoxy)silane 
• 1030367-79-3 2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenol 
• 1030367-96-4 2-(2-methyl-4-((2-phenyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)thio)phenoxy)acetic acid 
• 1417531-66-8 C₂₀H₁₇F₃N₂O₃ 
• 1417531-46-4 1-((5-((diethylamino)methyl)-4-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)isoxazol-3-yl)methyl)-2-(4-fluorobenzylthio)-6,7-dihydro-1H-cyclopenta[d]pyrimidin-4(5H)-one 
• 1417531-45-3 1-((5-(chloromethyl)-4-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)isoxazol-3-yl)methyl)-2-(4-fluorobenzylthio)-6,7-dihydro-1H-cyclopenta[d]pyrimidin-4(5H)-one 
• 1417531-44-2 2-(4-fluorobenzylthio)-1-((5-(hydroxymethyl)-4-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)isoxazol-3-yl)methyl)-6,7-dihydro-1H-cyclopenta[d]pyrimidin-4(5H)-one 
• 1417531-43-1 methyl 3-((2-(4-fluorobenzylthio)-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl)methyl)-4-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)isoxazole-5-carboxylate 
• 1417531-64-6 methyl 3-((4-oxo-2-thioxo-2,3,4,5,6,7-hexahydro-1H-cyclopenta[d]pyrimidin-1-yl)methyl)-4-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)isoxazole-5-carboxylate 

Relevant academic research and scientific papers

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS

The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

Synthesis, biological evaluation, and 3D QSAR study of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters as N -acylethanolamine acid amidase (NAAA) inhibitors

N-(2-Oxo-3-oxetanyl)carbamic acid esters have recently been reported to be noncompetitive inhibitors of the N-acylethanolamine acid amidase (NAAA) potentially useful for the treatment of pain and inflammation. In the present study, we further explored the

DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

Dicarboxylic Acid Derivatives and their Use

The present application relates to novel dicarboxylic acid derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, es

PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) and or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in the manufacture of a medicament for teating cardiovascular diseases, and processes for their preparation.

Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases

The present application relates to novel heterocyclic compounds, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especia